Theravance Long Term Investments vs Non Current Assets Total Analysis

TBPH Stock  USD 8.47  0.18  2.08%   
Theravance Biopharma financial indicator trend analysis is much more than just breaking down Theravance Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Theravance Biopharma is a good investment. Please check the relationship between Theravance Biopharma Long Term Investments and its Non Current Assets Total accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.

Long Term Investments vs Non Current Assets Total

Long Term Investments vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Theravance Biopharma Long Term Investments account and Non Current Assets Total. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Theravance Biopharma's Long Term Investments and Non Current Assets Total is -0.51. Overlapping area represents the amount of variation of Long Term Investments that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Theravance Biopharma, assuming nothing else is changed. The correlation between historical values of Theravance Biopharma's Long Term Investments and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Investments of Theravance Biopharma are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Long Term Investments i.e., Theravance Biopharma's Long Term Investments and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

-0.51
Relationship DirectionNegative 
Relationship StrengthVery Weak

Long Term Investments

Long Term Investments is an item on the asset side of Theravance Biopharma balance sheet that represents investments Theravance Biopharma intends to hold for over a year. Theravance Biopharma long term investments may include different instruments such as stocks, bonds, real estate and cash.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.
Most indicators from Theravance Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Theravance Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.As of now, Theravance Biopharma's Sales General And Administrative To Revenue is increasing as compared to previous years.
 2021 2022 2023 2024 (projected)
Total Operating Expenses293.0M130.5M110.7M105.2M
Cost Of Revenue7.3M6.6M6.1M5.7M

Theravance Biopharma fundamental ratios Correlations

0.730.280.410.5-0.460.45-0.180.580.70.55-0.140.130.820.04-0.90.230.670.50.720.61-0.270.73-0.480.66-0.85
0.730.440.460.48-0.190.32-0.080.60.560.150.280.420.420.07-0.660.560.550.330.370.38-0.190.56-0.250.34-0.56
0.280.440.82-0.150.09-0.30.40.330.750.15-0.46-0.230.270.32-0.59-0.07-0.11-0.3-0.070.590.590.72-0.04-0.03-0.27
0.410.460.82-0.20.21-0.390.220.460.870.15-0.57-0.390.430.66-0.640.16-0.21-0.36-0.050.650.430.83-0.22-0.03-0.44
0.50.48-0.15-0.2-0.450.92-0.670.54-0.04-0.070.470.690.33-0.14-0.30.130.840.920.78-0.05-0.45-0.02-0.70.71-0.6
-0.46-0.190.090.21-0.45-0.50.29-0.02-0.13-0.22-0.01-0.18-0.410.190.28-0.03-0.54-0.53-0.70.050.0-0.170.16-0.540.38
0.450.32-0.3-0.390.92-0.5-0.580.35-0.190.00.490.760.41-0.42-0.23-0.080.920.990.750.02-0.57-0.16-0.650.77-0.53
-0.18-0.080.40.22-0.670.29-0.58-0.340.120.05-0.2-0.21-0.21-0.280.06-0.14-0.45-0.59-0.670.140.490.10.56-0.630.49
0.580.60.330.460.54-0.020.35-0.340.560.25-0.090.170.430.36-0.640.240.370.310.50.33-0.270.56-0.620.4-0.76
0.70.560.750.87-0.04-0.13-0.190.120.560.56-0.64-0.410.640.49-0.890.170.07-0.150.320.760.221.0-0.210.26-0.67
0.550.150.150.15-0.07-0.220.00.050.250.56-0.51-0.420.5-0.11-0.66-0.140.230.010.450.58-0.270.60.090.43-0.47
-0.140.28-0.46-0.570.47-0.010.49-0.2-0.09-0.64-0.510.85-0.36-0.50.420.330.410.46-0.04-0.53-0.42-0.640.020.00.27
0.130.42-0.23-0.390.69-0.180.76-0.210.17-0.41-0.420.850.03-0.530.10.160.690.730.22-0.2-0.44-0.4-0.340.28-0.11
0.820.420.270.430.33-0.410.41-0.210.430.640.5-0.360.030.04-0.82-0.180.580.440.640.79-0.190.65-0.590.76-0.85
0.040.070.320.66-0.140.19-0.42-0.280.360.49-0.11-0.5-0.530.04-0.170.35-0.45-0.38-0.020.090.320.45-0.25-0.16-0.27
-0.9-0.66-0.59-0.64-0.30.28-0.230.06-0.64-0.89-0.660.420.1-0.82-0.17-0.04-0.48-0.26-0.6-0.820.08-0.910.41-0.60.85
0.230.56-0.070.160.13-0.03-0.08-0.140.240.17-0.140.330.16-0.180.35-0.040.03-0.010.03-0.22-0.250.170.13-0.24-0.08
0.670.55-0.11-0.210.84-0.540.92-0.450.370.070.230.410.690.58-0.45-0.480.030.930.790.27-0.590.11-0.510.83-0.64
0.50.33-0.3-0.360.92-0.530.99-0.590.31-0.150.010.460.730.44-0.38-0.26-0.010.930.780.04-0.58-0.11-0.640.76-0.55
0.720.37-0.07-0.050.78-0.70.75-0.670.50.320.45-0.040.220.64-0.02-0.60.030.790.780.26-0.430.36-0.590.88-0.82
0.610.380.590.65-0.050.050.020.140.330.760.58-0.53-0.20.790.09-0.82-0.220.270.040.26-0.050.75-0.280.44-0.63
-0.27-0.190.590.43-0.450.0-0.570.49-0.270.22-0.27-0.42-0.44-0.190.320.08-0.25-0.59-0.58-0.43-0.050.180.21-0.430.33
0.730.560.720.83-0.02-0.17-0.160.10.561.00.6-0.64-0.40.650.45-0.910.170.11-0.110.360.750.18-0.20.29-0.69
-0.48-0.25-0.04-0.22-0.70.16-0.650.56-0.62-0.210.090.02-0.34-0.59-0.250.410.13-0.51-0.64-0.59-0.280.21-0.2-0.620.74
0.660.34-0.03-0.030.71-0.540.77-0.630.40.260.430.00.280.76-0.16-0.6-0.240.830.760.880.44-0.430.29-0.62-0.79
-0.85-0.56-0.27-0.44-0.60.38-0.530.49-0.76-0.67-0.470.27-0.11-0.85-0.270.85-0.08-0.64-0.55-0.82-0.630.33-0.690.74-0.79
Click cells to compare fundamentals

Theravance Biopharma Account Relationship Matchups

Theravance Biopharma fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding55.6M62.3M69.5M73.6M55.3M53.3M
Total Assets408.8M469.1M374.8M607.4M382.0M418.6M
Other Current Liab57.8M76.1M37.9M(1.6M)24.8M40.9M
Total Current Liabilities111.7M123.6M58.6M28.7M24.8M23.5M
Other Liab28.0M2.2M2.7M91.5M105.2M110.5M
Accounts Payable4.8M6.8M3.1M1.6M1.5M1.4M
Other Assets6.1M3.3M4.1M201.9M232.2M243.8M
Inventory0.01.020.4M10.2M1.5M0.95
Other Current Assets7.1M10.4M8.6M7.7M13.6M8.4M
Total Liab632.7M772.8M713.4M165.6M169.0M160.6M
Property Plant Equipment12.6M16.4M53.3M11.9M13.7M16.5M
Total Stockholder Equity(223.8M)(303.8M)(338.6M)441.8M213.0M223.6M
Net Tangible Assets(169.4M)116.7M(338.6M)577.0M519.3M545.3M
Property Plant And Equipment Net59.2M59.7M53.3M52.0M45.4M33.1M
Current Deferred Revenue31.6M11.5M98K24K(5.4M)(5.2M)
Retained Earnings(1.2B)(1.5B)(1.7B)(853.9M)(909.1M)(954.6M)
Cash58.1M81.5M90.0M298.2M39.5M37.6M
Non Current Assets Total70.3M75.7M124.9M253.9M248.5M260.9M
Non Currrent Assets Other6.1M3.3M4.1M201.1M202.3M212.4M
Long Term Debt454.4M445.2M227.0M599.4M689.3M723.8M
Net Receivables50.6M69.7M57.6M16.8M17.5M27.9M
Short Term Investments222.8M211.5M83.5M29.3M62.9M112.2M
Liabilities And Stockholders Equity408.8M469.1M374.8M607.4M382.0M454.6M
Non Current Liabilities Total521.0M649.2M654.8M136.9M144.2M137.0M
Long Term Investments49.8M11.9M8.7M12.8M67.5M0.0
Property Plant And Equipment Gross59.2M16.4M53.3M52.0M66.9M70.3M
Total Current Assets338.5M393.3M249.9M353.5M133.5M126.9M
Accumulated Other Comprehensive Income145K47K0.0(15K)(65K)(68.3K)
Net Debt434.9M565.6M562.1M(224.1M)5.7M5.4M
Cash And Short Term Investments280.8M292.9M173.5M327.5M102.4M97.3M
Retained Earnings Total Equity(1.2B)(1.5B)(1.7B)(853.9M)(768.5M)(806.9M)
Capital Surpluse1.0B1.2B1.4B1.3B1.5B1.1B
Other Stockholder Equity1.0B1.2B1.4B1.3B1.1B1.1B
Non Current Liabilities Other21.3M1.8M2.7M1.7M33.7M35.4M
Short Long Term Debt Total492.9M647.1M652.1M74.1M45.2M43.0M
Long Term Debt Total454.4M445.2M227.0M228.0M262.2M330.2M

Currently Active Assets on Macroaxis

When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.95)
Revenue Per Share
1.249
Quarterly Revenue Growth
0.037
Return On Assets
(0.06)
Return On Equity
(0.19)
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.